Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Goldman Sachs initiates coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Sell rating and $21 price target, suggesting 8% downside.
The firm said the US market for Ampyra as largely defined and they do not see room for upside to consensus estimates which would be necessary to boost shares. Goldman also said the consensus is underestimating expenses, which could hit the stock.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $22.91 yesterday.
The firm said the US market for Ampyra as largely defined and they do not see room for upside to consensus estimates which would be necessary to boost shares. Goldman also said the consensus is underestimating expenses, which could hit the stock.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $22.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Rio Tinto (RIO) at Underweight
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
- Wells Fargo Starts Vivmark Residential (VMRK) at Overweight, 'Setting the mark for growth'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
